Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

How to enhance pCR in TNBC

BGICC 2019

17 - 18 Jan 2019

Published: 25 Jan 2019

Views: 1492

Rating:

Save

Prof Pierre Conte - Istituto Oncologico Veneto, Padova, Italy

Prof Pierre Conte speaks to ecancer at BGICC 2019 in Cairo on how to enhance pathological complete response (pCR) in triple negative breast cancer (TNBC).

He explains that it is now clear that patients who achieve pathological complete response after neoadjuvant treatment have a very good prognosis.

Prof Conte talks about the importance of identifying tumours in order to try to predict a pathological complete response, although this can be difficult due to the heterogenous nature of the tumours.

Related Videos

Neo-adjuvant therapy for different cancers in the Philippines

Dr Priscilla Caguioa - St Luke's Medical Center, Manila, Philippines

Neo-adjuvant therapy for different cancers in the Philippines ( Dr Priscilla Caguioa - St Luke's Medical Center, Manila, Philippines )

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+...

Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )

IORT at the Asian Hospital and Medical Center

Dr Aldine Basa - Asian Hospital and Medical Center, Manila, Philippines

IORT at the Asian Hospital and Medical Center ( Dr Aldine Basa - Asian Hospital and Medical Center, Manila, Philippines )

The TARGIT-A randomised trial: TARGIT-IORT versus whole breast radiation...

Dr Jayant Vaidya - University College London, London, UK

The TARGIT-A randomised trial: TARGIT-IORT versus whole breast radiation therapy: long-term local control and survival ( Dr Jayant Vaidya - University College London, London, UK )

Insights from TARGIT-A trial of targeted IORT during lumpectomy for breast...

Dr Jayant Vaidya - University College London, London, UK

Insights from TARGIT-A trial of targeted IORT during lumpectomy for breast cancer ( Dr Jayant Vaidya - University College London, London, UK )

The role of lymph nodes in stage 3 lung cancer

Prof Walter Weder - Privatklinik Bethanien,Zürich, Switzerland

The role of lymph nodes in stage 3 lung cancer ( Prof Walter Weder - Privatklinik Bethanien,Zürich, Switzerland )

Surgical management of Axilla: Past, present and future

Prof Terry Mamounas - Orlando Health Cancer Institute, Orlando, USA

Surgical management of Axilla: Past, present and future ( Prof Terry Mamounas - Orlando Health Cancer Institute, Orlando, USA )

Comment: LUMINA results show that women with low levels of the Ki67 biomarker...

Dr Corey Wayne Speers - University of Michigan, Ann Arbor, USA

Comment: LUMINA results show that women with low levels of the Ki67 biomarker can avoid outcomes related to radiotherapy ( Dr Corey Wayne Speers - University of Michigan, Ann Arbor, USA )

Biomarker guidance allows patients 55 or older with low-grade luminal A-type...

Dr Timothy J. Whelan - McMaster University, Ontario, Canada

Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to avoid radiation therapy ( Dr Timothy J. Whelan - McMaster University, Ontario, Canada )

More from ecancer